Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials.

BACKGROUND

T-cell redirecting therapies, notably chimeric antigen receptor T cells and bispecific antibodies, have revolutionized the treatment of hematologic malignancies. Their rapid expansion into solid tumors, alongside the emergence of next-generation agents, such as immunocytokines and CD28-costimulatory bispecifics, has brought cytokine release syndrome (CRS) to the forefront of clinical oncology. However, the absence of a unified grading system for these novel constructs remains a critical barrier to drug development and patient safety. Current toxicity management relies on disparate grading scales, leading to inconsistent reporting and hindering cross-trial comparisons. A fundamental challenge lies in the diagnostic ambiguity created by the significant clinical and temporal overlap among CRS, infusion-related reactions, and other diagnoses. Although fever, hypotension, and hypoxia are common denominators, their distinct pathophysiological drivers necessitate divergent therapeutic interventions.

DESIGN

We advocate for a paradigm shift from aggregate syndromic grading toward a granular, longitudinal reporting framework. This approach prioritizes the precise documentation of symptom kinetics, specific interventions (e.g. exact vasopressor requirements and oxygen flow rates), and real-time biomarker integration. By capturing high-fidelity data, researchers can retrospectively apply evolving criteria and develop more tailored, evidence-based management algorithms.

CONCLUSION

Transitioning to a standardized, symptom-driven reporting model is essential to navigate the complexities of 'Immuno-oncology 2.0.' Such a framework will harmonize safety assessments across global trials and ultimately optimize the therapeutic index of next-generation immunotherapies.